A phase 1 multi-centre, randomized, single-blind, steady-state study to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability after multiple-dose administration of three different doses of naronapride in patients with moderate idiopathic or diabetic gastroparesis compared to healthy subjects
NAT-022/BIO
Phase 1 other active
Quick answer
A phase 1 multi-centre, randomized, single-blind, steady-state study to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability after multiple-dose administration of three different doses of naronapride in patients with moderate idiopathic or diabetic gastroparesis compared to healthy subjects for Idiopathic or diabetic gastroparesis is a Phase 1 program (other) at Dr. Falk Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Dr. Falk Pharma GmbH
- Indication
- Idiopathic or diabetic gastroparesis
- Phase
- Phase 1
- Modality
- other
- Status
- active